National Health News:
Novartis CEO plays down prospects for Actelion bid: Blick
Novartis Chief Executive Joe Jimenez has played down suggestions the Swiss drugmaker could bid for Swiss biotech group Actelion, which is in talks with U.S. healthcare group Johnson & Johnson about a transaction. Asked by Swiss Sunday newspaper SonntagsBlick whether Novartis could emerge as a white knight, he said: "We have always said that we will concentrate on complementary acquisitions in the range of $2 billion to $5 billion." He did not elaborate. Actelion is worth nearly $20 billion at Friday's closing price.
Players: Kerr's marijuana admission could spark dialogue
OAKLAND, Calif. (AP) — David West has undergone four surgeries in his long NBA career: left knee, right elbow and right foot twice to fix a couple of toes.
The snake-catching tribe saving lives in India
A small scythe, a crowbar and a bundle of canvas bags are all that Kali and Vedan carry when they venture into the fields of southern India to catch some of the world's deadliest snakes. Since it began in the 1970s, the Irula snake-catchers' cooperative on the outskirts of the southern city of Chennai has revolutionised the treatment of snake-bites in India, enabling it to produce enough anti-venom to supply hospitals across the country. It also provides much-needed income for the Irula, one of the region's most deprived groups, who used to hunt snakes and sell the skins but lost their livelihood overnight when India banned the practice in 1972.